The most serious complication of factor VIII (FVIII) replacement therapy is the occurrence of
anti‐FVIII alloantibodies that can strongly reduce or abolish the effect of human FVIII …

Introduction Emicizumab prophylaxis improves coagulation function in congenital
hemophilia A, regardless of inhibitor presence. We recently reported that emicizumab …

Objective To establish clear priorities for the care of patients with acquired hemophilia A
(AHA) by proposing 10 key principles of practical, holistic AHA management. Method These …

Acquired haemophilia A (AHA) is a rare and severe haemorrhagic autoimmune disease
caused by autoantibodies directed against factor VIII (FVIII). Treatment is based on two …

The treatment of patients with acquired hemophilia is challenging due to life-threatening
hemorrhages, delayed response, and adverse effects to immunosuppressive agents. Even …

Abstract Background Acquired hemophilia A (AHA) is a potentially life‐threatening bleeding
disorder caused by factor VIII (FVIII) autoantibodies, involving various immunoglobulin (Ig) …

Although the estimated incidence of acquired haemophilia A (AHA) in Singapore is similar to
those reported in the literature, we have observed differences in the frequency of their …

Background. Acquired hemophilia A (AHA) is a potentially life‐threatening autoimmune
hemostatic disorder where autoantibodies that disrupt the functions of factor VIII (FVIII) are …

Objective Because acquired hemophilia (AH) is a rare entity in systemic lupus
erythematosus (SLE), we aimed to investigate the clinical features of SLE-related AH in …

Consenso de hemofilia en México SciELO - Scientific Electronic Library Online vol.157 suppl.1
índice de autores índice de materia búsqueda de artículos Home Page lista alfabética de …